Chanticleer
The ASX health giant riding COVID’s second wave
Fisher & Paykel Healthcare's humidifiers have become vital to the treatment of COVID-19 cases. But investors are starting to look beyond the virus.
Updated
Australia and New Zealand might have largely eliminated COVID-19, but for the $19 billion ASX and NZX-listed group Fisher & Paykel Healthcare, the fight is far from over.
Since the outbreak of the pandemic this year, F&P has been scrambling to keep up with the demand from hospitals for its humidifiers, which have become vital to the treatment of the disease.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles